Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities

DJ Grunhagen, JHW (Johannes) de Wilt, AN Geel, Kees Verhoef, Lex Eggermont

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Scopus)

Abstract

Limb-sparing surgery has become all the more important in soft tissue sarcoma (STS) of the extremities since we learned that amputation does not improve survival of these patients. In bulky tumours, however, preoperative strategies to reduce tumour size are then required. Isolated limb perfusion (ILP) with tumour necrosis factor (TNF) has been developed as a biochemotherapeutic therapy to act both on the tumour-associated vasculature and on the tumour itself. It has shown to be a very potent treatment modality, as in early reports response rates were around 80%. Limb salvage could then be achieved in a quite similar percentage. Many confirmatory studies have been performed since, with consistent results even in patients with multiple tumours, after extensive radiotherapy or with metastatic disease, all at the cost of very limited toxicity. This chapter gives an overview of the ILP studies performed in patients with soft tissue limb sarcoma, discusses the mechanism of TNF-mediated vasculotoxic effects on tumour vasculature, and places TNF-based ILP in the multimodality treatment of these patients with extensive STS of the extremities.

Original languageEnglish
Pages (from-to)257-270
Number of pages14
JournalRecent Results in Cancer Research
Volume179
DOIs
Publication statusPublished - 2009

Fingerprint

Dive into the research topics of 'Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities'. Together they form a unique fingerprint.

Cite this